Covidien Introduces TussiCaps ER Capsules in US
Covidien, a provider of healthcare products, has announced the US availability of TussiCaps extended-release capsules, the first and only hydrocodone antitussive oral capsule to provide powerful cough suppression for up to 12 hours.
TussiCaps, which is approved by the FDA, is now available by prescription in 10mg/8mg capsules through wholesalers and pharmacies in the US.
TussiCaps extended-release capsules are indicated for the relief of cough and upper respiratory symptoms associated with allergies and colds.
Chuck Bramlage, president of pharmaceutical products at Covidien, said: “TussiCaps capsules offer patients a unique approach to handling the challenges of measuring liquid cough medications. Our commitment to increasing patient safety and helping to reduce the potential for dosing errors is demonstrated in TussiCaps, which offers more precise and convenient dosing than liquid formulations.”